Advancements are happening everyday

Treatment and research are intimately linked. The best treatments today may be upstaged by new therapies discovered in research in the future. Take your time to learn about treatment options currently available and new ones that are on the way. 

Advancements are happening everyday

Treatment and research are intimately linked. The best treatments today may be upstaged by new therapies discovered in research in the future. Take your time and learn about what treatment options are now available and the new ones are on the way. 

Treatment and Research: 4 Things to Know

CLL patients are living longer than ever.

The life expectancy of patients diagnosed with CLL/SLL has improved every decade, largely because of improved care made possible by new treatments and research.

CLL treatments are better than ever.

In almost every setting and in almost every subgroup studied, the newer targeted therapies approved since 2015 have proven superior to older protocols using chemotherapy.

Better single agents and drug combinations show promise.

New improved medications and drug combinations are constantly improving outcomes.

Research drives success.

CLL/SLL is not a solved problem and never will be without new treatments and more research.

CLL patients are living longer than ever.

The life expectancy of patients diagnosed with CLL/SLL has improved every decade, largely because of improved care made possible by new treatments and research.

CLL treatments are better than ever.

In almost every setting and in almost every subgroup studied, the newer targeted therapies approved since 2015 have proven superior to older protocols using chemotherapy.

Better single agents and drug combinations show promise.

New improved medications and drug combinations are constantly improving outcomes.

Research drives success.

CLL/SLL is not a solved problem and never will be without new treatments and more research.

FEATURE

ASH 2021: Real-World Treatment Patterns and Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Receiving First-Line (1L) Therapy in the United States (US)

There have been many advances in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) treatments over the past decade, with several potent novel agents targeting molecular pathways within CLL cells receiving FDA approval.

At the American Society of Hematology Annual Meeting and Exposition, ASH 2021, Dr. Anthony Mato et al. reports the results from this large multi-centered retrospective study on the evolution of molecular testing patterns, treatment patterns, and clinical outcomes over time in patients receiving first-line CLL treatment in a real-world US database. Read More

ADDITIONAL READING

Acalabrutinib plus high-frequency, low-dose subcutaneous rituximab is tolerable and effective. In addition, because it can be administered at home, it is more convenient and can decrease patient infection risk during pandemics. However, while it does control disease, it does not lead to undetectable measurable residual disease (uMRD).
RECENT NEWS

When appropriate, the CLL Society will be posting updates and background information on the present Coronavirus pandemic focusing on reliable primary sources of information and avoiding most of the news that is not directly from reliable medical experts or government and world health agencies.